ReviewNeuroendocrine aspects of catamenial epilepsy
Highlights
► This review describes the neuroendocrinological aspects of catamenial epilepsy. ► Neurosteroids such as allopregnanolone play a critical role in catamenial epilepsy. ► Alterations of GABA-A receptor plasticity and function are evident in catamenial models. ► Synthetic neurosteroids may be useful for pharmacotherapy of catamenial epilepsy.
Introduction
Epilepsy is one of the most common chronic neurological disorders characterized by the unpredictable occurrence of seizures that differ in type, cause, and severity. However, seizures do not occur randomly in many women with epilepsy. Seizure clusters occur with a temporal periodicity following circadian or lunar periodicity. In women with epilepsy, seizure periodicity may conform to the menstrual cycle according to a “menstrual clock” provided by a common phase marker of the onset of menses (Gowers, 1881). Catamenial epilepsy, derived from the Greek word katomenios, meaning “monthly”, is characterized by seizures that cluster around specific points in the menstrual cycle (Fig. 1). Catamenial epilepsy is a multifaceted neuroendocrine condition in which seizures are most often clustered around perimenstrual or periovulatory period. Epilepsy affects an estimated 1.3 million women in the United States (Kaplan et al., 2007, Pennell, 2008). Catamenial epilepsy affects from 10 to 70% of women with epilepsy (Bazan et al., 2005, Gilad et al., 2008, Herzog et al., 2004, Reddy, 2009). The large variation in the prevalence of catamenial epilepsy is partly because of methodological differences such as the criteria used for defining seizure exacerbation in relation to menstrual cycle, patients' self-report, diaries, and other records of seizures relating to menses. Overall, these studies support the prevailing notion that at least 1 in every 3 women with epilepsy shows catamenial seizure exacerbation. Catamenial epilepsy is a form of intractable epilepsy because catamenial seizures are often quite resistant to available drug treatments. Presently, there is no effective prevention or cure for catamenial epilepsy. There is a large gap in our understanding of what changes occur in the brain in relation to the hormonal fluctuations associated with catamenial epilepsy and how these changes alter sensitivity to anticonvulsant drugs. Thus, a detailed understanding of the patterns and pathophysiology is essential for the development of rational approaches for the prevention or treatment of catamenial epilepsy.
Three types of catamenial seizures, perimenstrual (C1), periovulatory (C2), and inadequate luteal-phase (C3), have been identified (Herzog et al., 1997) (Fig. 1; Table 1). The perimenstrual type is the most common clinical type. Perimenstrual and periovulatory types are illustrated in Fig. 1. The specific pattern of catamenial epilepsy can be identified simply by charting menses and seizures and obtaining a mid-luteal phase serum progesterone (P) level to distinguish between normal and inadequate luteal phase cycles (Herzog et al., 2008, Quigg et al., 2009). The diagnosis of catamenial epilepsy is mainly based on the assessment of menstruation and seizure records (Foldvary-Schaefer and Falcone, 2003, Herzog, 2006). The simple approach of evaluation of catamenial epilepsy, that is, whether the patient's seizures tend to worsen at certain points of the menstrual cycle, is to record seizure diary in relation to menstrual cycle. Using the first day of menstrual bleeding as the first day of the cycle, the menstrual cycle is divided into four phases: (a) menstrual phase, days − 3 to + 3; (b) follicular phase, days + 4 to + 9; (c) ovulatory phase, days + 10 to + 16; and (d) luteal phase, days + 17 to − 4 (see Fig. 1). The number of seizures in each phase is counted for at least 2 cycles and a two-fold or greater increase in frequency during a particular phase of the menstrual cycle can be used as diagnostic criteria of catamenial epilepsy as demonstrated by a mathematical waveform (cosinor) analysis (Quigg et al., 2009).
In the primary clinical type, perimenstrual catamenial epilepsy (C1), women with epilepsy experience an increase in seizure activity before, during or after the onset of menstruation (Reddy, 2009). Catamenial epilepsy is observed in women with ovulatory or anovulatory cycles. Women with ovulatory cycles could experience either the perimenstrual or periovulatory catamenial types or even both within a single cycle (Bauer, 2001, Bauer et al., 1998). The diagnosis of ovulatory or anovulatory cycles is often made by estimating the midluteal phase P levels. P levels lower than 5 ng/ml during days 20 through 22 of the cycle would certainly indicate inadequate luteal phase. Subjects can be examined by pelvic-abdominal ultrasound to measure the size of mature graffian follicle as a sign of ovulation. About 16.5% of cycles in study subjects are found to be anovulatory (Herzog et al., 2004), and these women showed a third type, referred to as inadequate luteal-phase or anovulatory luteal seizures.
This review describes the neuroendocrinological aspects of catamenial epilepsy. It focuses on the role of hormones and GABA-A receptor-modulating neurosteroids in the pathophysiology of catamenial epilepsy. It also summarizes the promise of neurosteroid analogs as specific treatment for catamenial seizures in women with epilepsy.
Section snippets
Pathophysiology of catamenial epilepsy
The exact cause of catamenial epilepsy remains unclear. Catamenial epilepsy is among the oldest neurological disorders known with early reports in 1881 (Gowers, 1881), yet the molecular mechanisms involved in the pathophysiology of catamenial epilepsy are not well understood. Catamenial epilepsy is a multifaceted condition attributed to numerous causes. Epilepsy typically develops due to certain genetic defect or often after a presumed initiating injury. Catamenial epilepsy, in many cases, is
Role of hormones and neurosteroids in the pathophysiology of catamenial epilepsy
Steroid hormones play a key role in the neuroendocrine control of neuronal excitability and seizure susceptibility. As illustrated in Fig. 1, cyclical changes of ovarian hormone estrogens and P are now widely believed to be important in the pathogenesis of catamenial epilepsy. Generally, estrogens are found to be proconvulsant, while P has powerful antiseizure effect and reduces seizures, and thus they play a central role in the pathophysiology of catamenial epilepsy (Reddy, 2009). There is
Animal models of catamenial epilepsy: implication for understanding the molecular mechanisms
Conventional seizure models, which are largely based on the utilization of acutely induced seizures in naive animals, are not suitable because they do not allow testing of specific therapies that are targeted to catamenial epilepsy. These models are clearly different from such models as kindling, pilocarpine or chronic kainic acid that induce severe damage and remodeling response in the brain and thereby result in secondary seizures. Generally, animal models of catamenial epilepsy could be
Hormonal and neurosteroid-based treatment of catamenial epilepsy
Presently there is no specific, FDA-approved drug treatment for catamenial epilepsy. The conventional AEDs are the mainstay for the management of catamenial seizures in women. Approximately one third of women with epilepsy use more than one AED appropriate to their seizure type. This is partly because catamenial seizures are often refractory to conventional AEDs. Many of these drugs are prescribed for the treatment of catamenial epilepsy without direct studies of effectiveness, with their use
Conclusions
Catamenial epilepsy is a specific form of pharmacoresistant epilepsy that impacts a substantial proportion (~ 70%) of an estimated 1.5 million women of child-bearing age with epilepsy in the United States. Catamenial epilepsy is a multifaceted neuroendocrine condition. Although ovarian hormones play a central role, the exact cause of catamenial epilepsy is unknown. Despite the increased information, there is a large gap in our understanding of catamenial epilepsy. Experimental studies to this
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The original research described in this article was supported in part by the NIH grants NS051398, NS052158 and NS071597 (to D.S.R.) and the seed grant of TAMHSC Women's Health in Neuroscience (WHIN) program. The author thanks Chase Carver for reading the manuscript.
References (123)
- et al.
Hormonal and gestational parameters in female rats submitted to the pilocarpine model of epilepsy
Epilepsy Res.
(1998) Steroid hormones in the brain: several mechanisms?
- et al.
The influence of subunit composition on the interaction of neurosteroids with GABAA receptors
Neuropharmacology
(2002) - et al.
Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy
Exp. Neurol.
(2006) - et al.
The sticky issue of neurosteroids and GABAA receptors
Trends Neurosci.
(2010) - et al.
Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides
Front. Neuroendocrinol.
(2009) - et al.
Steroid hormones affect limbic afterdischarge thresholds and kindling rates in adult female rats
Brain Res.
(1999) - et al.
Clobazam in catamenial epilepsy: a model for evaluating anticonvulsants
Lancet
(1982) - et al.
Neurosteroid withdrawal regulates GABAA receptor α4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway
Neuroscience
(2010) - et al.
Lamotrigine and catamenial epilepsy
Seizure
(2008)